Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible
- PMID: 37423230
- DOI: 10.1016/S0140-6736(23)00807-3
Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible
Conflict of interest statement
HO'S has received honorarium from Amgen and expenses from Takeda, all outside the scope of the submitted work. SP has received honoraria from Amgen, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GlaxoSmithKline, Guardant Health, Incyte, Janssen, Lilly, Merck Serono, Merck, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, and Turning Point Therapeutics; honoraria for educational lectures from AstraZeneca, Bayer, Guardant Health, Janssen, Merck Serono, Roche, and Takeda; and provided expert testimony for Roche and Merck Serono, all in the field of precision medicine and lung cancer drug development.
Comment on
-
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical